European Equities Traded in the US as American Depositary Rise in Friday Trading, Up Over 1% for Week

MT Newswires Live11-23

European equities traded in the US as American depositary receipts were trending modestly higher late Friday morning, rising 0.19% to 1,316.54 on the S&P Europe Select ADR Index, which is up approximately 1.2% for the week.

From continental Europe, the gainers were led by biotech firm BioNTech (BNTX) and medical device maker EDAP TMS (EDAP), which rose 3.6% and 2.6%, respectively. They were followed by internet browser company Opera (OPRA) and pharmaceutical company Ascendis Pharma (ASND), which were up 2.1% each.

The decliners from continental Europe were led by biopharmaceutical company Genfit (GNFT) and financial services company Banco Santander (SAN), which dropped 4.8% and 3.9%, respectively. They were followed by financial services companies ING (ING) and Banco Bilbao Vizcaya Argentaria (BBVA), which fell 2.7% and 2%, respectively.

From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Amarin (AMRN), which climbed 13% and 5.6% higher, respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and pharmaceutical company AstraZeneca (AZN), which increased 5.5% and 2.9%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and TC Biopharm (TCBP), which lost 12% and 3.9%, respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Adaptimmune Therapeutics (ADAP), which were down 3.1% and 2.5%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment